$1,318.00
This Market Spotlight report covers the Cutaneous T-Cell Lymphoma (CTCL) market, comprising key marketed and pipeline drugs, clinical trials, upcoming and regulatory events, recent events and analyst opinion, probability of success, a 10-year disease incidence and prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
This Market Spotlight report covers the Cutaneous T-Cell Lymphoma (CTCL) market, comprising key marketed and pipeline drugs, clinical trials, upcoming and regulatory events, recent events and analyst opinion, probability of success, a 10-year disease incidence and prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
10 TREATMENT
10 Skin-directed therapy
10 Systemic therapy
12 EPIDEMIOLOGY
14 Incidence methodology for the US and five major European markets
16 Prevalence methodology for the US and five major European markets
19 MARKETED DRUGS
22 PIPELINE DRUGS
29 RECENT EVENTS AND ANALYST OPINION
29 Ontak for CTCL (April 6, 2022)
30 IPH4102 for CTCL (June 22, 2021)
31 HyBryte for CTCL (October 22, 2020)
32 Cobomarsen for CTCL (October 5, 2020)
34 KEY UPCOMING EVENTS
35 KEY REGULATORY EVENTS
35 Frustration Over English Funding Rejection For Zytiga And A Win For Ledaga
36 PROBABILITY OF SUCCESS
37 LICENSING AND ASSET ACQUISITION DEALS
37 Equillium To Acquire Bioniz Therapeutics
37 Verity Pharmaceuticals And Helsinn Sign Exclusive Agreement To Promote Akynzeo And Valchlor In Puerto Rico
37 Dr. Reddy’s Sells Oncology Candidate To Citius
38 REVENUE OPPORTUNITY
39 CLINICAL TRIAL LANDSCAPE
40 Sponsors by status
41 Sponsors by phase
42 Recent events
44 BIBLIOGRAPHY
45 APPENDIX
LIST OF FIGURES
14 Figure 1: Global trends in incident cases of CTCL, 2017–26
16 Figure 2: Trends in incident cases of CTCL, US and 5 Euro, 2017–26
22 Figure 3: Overview of pipeline drugs for CTCL in the US
23 Figure 4: Pipeline drugs for CTCL, by company
23 Figure 5: Pipeline drugs for CTCL, by drug type
23 Figure 6: Pipeline drugs for CTCL, by classification
30 Figure 7: Ontak for CTCL (April 6, 2022): Phase III – E7777-G000-302
34 Figure 8: Key upcoming events in CTCL
36 Figure 9: Probability of success in the hematologic pipeline
39 Figure 10: Clinical trials in CTCL
39 Figure 11: Top 10 drugs for clinical trials in CTCL
40 Figure 12: Top 10 companies for clinical trials in CTCL
40 Figure 13: Trial locations in CTCL
41 Figure 14: CTCL trials status
42 Figure 15: CTCL trials sponsors, by phase
LIST OF TABLES
13 Table 1: Global incident cases of CTCL, 2017–26
15 Table 2: Incident cases of CTCL, US and 5 Euro, 2017–26
17 Table 3: 10-year prevalent cases of CTCL, US and 5 Euro, 2017–26
18 Table 4: Five-year prevalent cases of CTCL, US and 5 Euro, 2017–26
20 Table 5: Marketed drugs for CTCL
25 Table 6: Pipeline drugs for CTCL in the US
29 Table 7: Ontak for CTCL (April 6, 2022)
31 Table 8: IPH4102 for CTCL (June 22, 2021)
32 Table 9: HyBryte for CTCL (October 22, 2020)
33 Table 10: Cobomarsen for CTCL (October 5, 2020)
38 Table 11: Historical global sales, by drug ($m), 2017–21
38 Table 12: Forecasted global sales, by drug ($m), 2022–26
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!